Almirall to license Eloxx’s ZKN-013 for rare skin conditions
Pharmaceutical Technology
MARCH 14, 2024
Almirall has signed a licence agreement to gain the rights for Eloxx Pharmaceuticals’ ZKN-013 for rare dermatological disease indications.
Almirall, Novo Nordisk Reach Licensing Agreement Surrounding IL-21 Blocking Monoclonal Antibodies
Pharmaceutical Commerce
FEBRUARY 20, 2024
As part of the agreement, Novo will be paid both development and commercial milestone payments for NN-8828, is currently in Phase II of non-dermatological indications.
Dermatology 
52
52 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Crescita Announces Licensing Agreement for Pliaglis; in China
The Pharma Data
NOVEMBER 4, 2020
TSX: CTX) (OTC US: CRRTF) (“Crescita” or the “Company”), a growth-oriented, innovation-driven Canadian commercial dermatology company with in-house research & development (“R&D”) and manufacturing capabilities, today announced that it has entered into an exclusive agreement with Juyou-Biotechnology Co.
Licensing 40
40 
Fall Clinical Dermatology 2020: Lilly and Incyte Showcase Positive New Data for Baricitinib in Adult Patients with Alopecia Areata
The Pharma Data
OCTOBER 29, 2020
30, 2020 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today new data for baricitinib (marketed as OLUMIANT ® ) will be presented at the annual Fall Clinical Dermatology meeting taking place virtually October 29-November 1, 2020. INDIANAPOLIS , Oct. Skin-related diseases are more than skin deep.
Dermatology 52
52 
First biologic approved in Scotland for hidradenitis suppurativa since 2016
Drug Discovery World
FEBRUARY 16, 2024
It is licensed for adults with active moderate to severe hidradenitis suppurativa (HS) (acne inversa) who have responded inadequately to conventional systemic HS therapy. Novartis’ Cosentyx (secukinumab) is now available in Scotland, following positive advice from the Scottish Medicines Consortium (SMC).
Dermatology 64
64 
Lebrikizumab Could Soon Be a New Treatment for Atopic Dermatitis
XTalks
APRIL 17, 2023
These results are very promising for patients with atopic dermatitis,” said Jonathan Silverberg, MD, professor of dermatology at George Washington University School of Medicine & Health Sciences and co-investigator of the studies, in the company’s press release.
Dermatology 97
97 
Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis
pharmaphorum
SEPTEMBER 16, 2022
Atopic dermatitis (AD) is a highly prevalent chronic dermatological disease, with symptoms which include itching, dry skin, severe pain, and inflammation – all of which create considerable stress in the daily lives of patients and often negatively affect their day-to-day and long-term well-being.
Dermatology 99
99 
Almirall joins IL-2 push in autoimmunity with $507m Simcere deal
pharmaphorum
SEPTEMBER 30, 2022
Almirall has licensed an interleukin-2 (IL-2) drug from China’s Simcere Pharma, joining the ranks of companies looking at blocking the cytokine as a way to treat autoimmune diseases. Last year, Merck & Co paid $1.85 It has also reached a deal with Ablexis to use its antibody development platform in therapeutics.
Licensing 52
52 
J&J presents successful data from plaque psoriasis trial
Drug Discovery World
MARCH 13, 2024
“Data from the FRONTIER 2 study showed that the skin clearance as seen by PASI 75 and higher-bar PASI 90 and 100 responses at 16 weeks was maintained at 52 weeks with no new safety signals across all JNJ-2113 treatment groups,” said Dr Laura Ferris, Professor of Dermatology, University of Pittsburgh.
Trials 52
52 
Almirall demonstrates resilient performance year to date despite COVID-19 impacts
The Pharma Data
NOVEMBER 8, 2020
Almirall strengthens its leadership in medical dermatology by reinforcing its management team in France and obtaining reimbursement in France of Ilumetri ® (tildrakizumab) for treating moderate to severe chronic plaque psoriasis in adults. Dermatology shows resilience in Europe and initial signs of recovery in the US.
Dermatology 52
52 
UNION Therapeutics-Innovent’s collaboration; Delix Therapeutics bags $ 70 M; Biohaven’s Verdiperstat clinical trial result; Intra-Cellular’s CAPLYTA Phase III study
Delveinsight
SEPTEMBER 28, 2021
Innovent, UNION Therapeutics Set to Advance Dermatology Market in China. Innovent Biologics and UNION therapeutics have announced a strategic and licensing collaboration to develop and commercialize Orismilast , a next-generation PDE4 inhibitor for inflammatory dermatology conditions in China.
SkinVive by Juvéderm: The New Dermal Filler Coming to the US
XTalks
MAY 22, 2023
According to Allergan Aesthetics, SkinVive is slated for commercial availability within the next six months, exclusively through licensed physicians and practitioners. I am excited to add this unique offering to my dermatologic treatment regimen for my patients,” added Dr.
Filler 92
92 
Sanofi wagers $400m on miRecule muscular dystrophy therapy
pharmaphorum
OCTOBER 5, 2022
Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRecule. The aim will be to identify promising candidates in areas of “unmet patient need.”
RNA 105
105 
Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema
pharmaphorum
OCTOBER 1, 2021
Further details from the study – which involved four doses of either a high or low dose of the antibody over a 12-week period and a clinical assessment at 16 weeks – were presented at the EADV dermatology congress this week. The post Key drug in Sanofi’s $1.45bn Kymab buyout shows promise in eczema appeared first on.
Drugs 103
103 
First oral therapy for severe alopecia areata approved in UK
Drug Discovery World
OCTOBER 7, 2022
The MHRA has granted marketing authorisation for Eli Lilly’s baricitinib (Olumiant), the first licensed JAK inhibitor for the treatment of severe alopecia areata in adult patients. . This is an important authorisation for patients as previously there has never been a licensed oral therapy for adults with severe alopecia areata.” .
Licensing 52
52 
Nearly 40% of Adults with Alopecia Areata Taking OLUMIANT® 4-mg Saw at Least 80% Scalp Hair Coverage at 52 Weeks in Lilly’s Pivotal Phase 3 Studies
The Pharma Data
MARCH 27, 2022
These 52-week pooled analyses demonstrate continued improvement in scalp, eyebrows and eyelash hair regrowth from 36-week results published today in the New England Journal of Medicine and presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress. In February 2022, the U.S. ” About OLUMIANT®.
Dermatology 40
40 
Lilly’s lebrikizumab significantly improved skin clearance and itch in people with moderate-to-severe atopic dermatitis in two Phase 3 trials
The Pharma Data
AUGUST 16, 2021
associate professor of dermatology at George Washington University School of Medicine and Health Sciences in Washington, DC, and a principal investigator of the ADvocate 2 trial. Key secondary endpoints were measured by the IGA, EASI, the Pruritus Numeric Rating Scale, Sleep-Loss due to Pruritus and the Dermatology Life Quality Index.
Dermatology 40
40 
MoonLake launches, licensing in Merck KGaA’s Cosentyx challenger sonelokimab
pharmaphorum
MAY 4, 2021
There’s a new biotech on the scene after MoonLake Immunotherapeutics launched on a mission to develop sonelokimab, a potential inflammatory diseases drug in-licensed from Germany’s Merck KGaA. MoonLake has swiftly in-licensed the drug discovered by Sanofi’s Ablynx unit, with plans to develop the drug targeting IL-17A and F.
Licensing 52
52 
First biologic therapy for young children with severe eczema
Drug Discovery World
SEPTEMBER 16, 2022
The therapy is already licensed in the UK for adults and children aged six to 18, and was approved by the FDA in June 2022 for use in younger children.
Antibody 52
52 
CoolSculpting® by Allergan Aesthetics Expands Body Contouring Portfolio With CoolSculpting® Elite
The Pharma Data
FEBRUARY 5, 2021
American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. As with any medical procedure, a consultation should be done by a licensed healthcare professional to determine if the patient is a candidate for treatment. N= 3,525 total study population.
Cosmetics 52
52 
Vitiligo Miracle Video – Heal Vitiligo In 7 Days
The Pharma Data
MAY 13, 2021
Featuring latest research from American Journal of Clinical Dermatology. Description: 1 Weird Trick To Easily Cure Vitiligo For Good In As Little As 7 Days – Guaranteed! Scientific References. For program support please. contact us here. For order support please. contact Clickbank here.
Production 52
52 
Update on US regulatory review of Fasenra in chronic rhinosinusitis with nasal polyps
The Pharma Data
MARCH 15, 2022
The US Food and Drug Administration (FDA) has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for Fasenra (benralizumab) for patients with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP). Fasenra was developed by AstraZeneca and is in-licensed from BioWa, Inc.,
Trials 52
52 
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
The Pharma Data
AUGUST 17, 2021
The company recently announced Breakthrough Therapy designation for donanemab and its intention to submit a biologics license application (BLA) under the accelerated approval pathway later this year. Prior to joining Loxo Oncology, Van Naarden served in various biotechnology investment, operations and advisory roles.
Medicine 52
52 
Amgen pays Kyowa $400m upfront for OX40 eczema drug
pharmaphorum
JUNE 2, 2021
The licensing deal expands Amgen’s pipeline of immunological drugs, currently headed by just-filed tezepelumab for asthma, and also rekindles a fruitful partnership with Kyowa that came to an end a few years ago.
Drugs 52
52 
Eight out of Ten Patients Maintained Skin Clearance at One Year in Lilly’s Lebrikizumab Atopic Dermatitis Monotherapy Trials
The Pharma Data
JUNE 7, 2022
With these data, Lilly plans to submit a Biologics License Application (BLA) to the U.S. Almirall has licensed the rights to develop and commercialize lebrikizumab for the treatment of dermatology indications, including AD, in Europe. Almirall S.A.’s ’s Chief Scientific Officer.
Trials 40
40 
Lymecycline for ACNE: Questions & Answers
Druggist
MARCH 17, 2021
Although licensed for acne, minocycline is rarely prescribed in the UK. Strauss JS, Krowchuk DP, Leyden JJ, American Academy of Dermatology/American Academy of Dermatology Association, et al. The effectiveness of lymecycline was compared to another tetracycline, minocycline. Available at: [link] Accessed on 17/03/2021.
Bacteria 59
59 
Medical Aesthetics: “Redefining Beauty through Medical Expertise”
Roots Analysis
JANUARY 3, 2024
These invasive procedures can also be performed at a medical aesthetic clinic and also at hospitals and dermatology centers to make it accessible for various end user. Increased awareness among people and a higher number of licensed medical professionals can help in driving the future of this market.
Filler 40
40 
FDA Accepts for Review Pfizer’s Supplemental Application for ABRILADA™ (adalimumab-afzb) Interchangeability
The Pharma Data
FEBRUARY 25, 2022
Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). Pfizer Inc. NYSE: PFE) today announced that the U.S.
FDA Approval 52
52 
Pediatric Psoriasis vs. Eczema
Olympian Clinical Research
AUGUST 19, 2022
The Benefits of Clinical Research for Pediatric Dermatology Conditions. These studies are done under the supervision of a licensed physician and are conducted with the safety of participants in mind. Moreover, be aware of soaps, detergents, or other products that may trigger your child’s eczema flare-ups and avoid using them.
Calamine lotion for chickenpox skin itchiness
Druggist
OCTOBER 25, 2020
Nevertheless, calamine lotion is licensed in the UK for symptomatic relief of skin conditions including itchiness. Both products have the same licensed use: symptomatic relief of mild sunburn and relief from other skin conditions. Liquid antihistamine – chlorphenamine (Piriton syrup) is licensed for this indication.
Production 52
52 
Tiziana announces appointment of Dr Neil Graham MBBS, MD, MPH as Chief Medical Officer
The Pharma Data
JANUARY 12, 2021
Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. He has in depth Global Development Expertise (e.g.
Life Science 52
52 
New Drug Application for baricitinib for the treatment of moderate to severe atopic dermatitis
The Pharma Data
APRIL 6, 2021
Ongoing research for baricitinib, an oral JAK inhibitor discovered by Incyte and licensed to Lilly, in adult and pediatric AD, alopecia areata (AA), systemic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA), COVID-19 and for its approved indication for rheumatoid arthritis (RA) continues. About Lilly in Dermatology.
Drugs 52
52 
Innovation Pharmaceuticals’ Brilacidin for the Treatment of COVID-19 Receives FDA Fast Track DesignationPhase 2 clinical trial of Brilacidin for COVID-19 anticipated to commence this month
The Pharma Data
JANUARY 13, 2021
(IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A.
Dermavant claims its first approval as FDA clears psoriasis drug
pharmaphorum
MAY 25, 2022
Tapinarof was GSK’s lead drug in immuno-inflammation R&D back in 2018 before it was licensed by Dermavant in a £250 million ($330 million) deal. It’s also in clinical testing for atopic dermatitis or eczema, with results due next year. Image by Anastasia Gepp from Pixabay.
Drugs 52
52 
17 creams to STOP ITCHING FAST
Druggist
DECEMBER 9, 2020
Clobetasone has a narrow licensed use. Dactacort has also antibacterial properties and is one of few over the counter creams licensed for bacterial infections. An interesting licensed use for Eurax cream is the treatment of scabies and itchy skin infestation in the skin. E45 Dermatological Itch Relief Cream, 100g.
Pharmacy 97
97 
Concert Pharmaceuticals Reports Third Quarter 2020 Financial Results and Provides Company Update
The Pharma Data
NOVEMBER 4, 2020
Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology.
Avillion/Merck psoriasis nanobody hits the mark in phase 2
pharmaphorum
APRIL 26, 2021
Merck licensed sonelokimab (M1095) from Ablynx in 2013, and four years later formed a partnership with Avillion to carry out phase 2 and 3 testing of the drug. The drug is a nanobody, a molecule around one-tenth the size of a regular antibody derived from camelid species such as the llama.
Antibody 52
52 
RYBREVANTTM (amivantamab-vmjw) in the Treatment of Patients with Advanced Non-Small.
The Pharma Data
AUGUST 19, 2021
entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. Dermatologic Adverse Reactions 7. For Grade 3 reactions, add oral steroids and consider dermatologic consultation. 8] , [9] , [10] , [11] , [12]. **In In 2018, Janssen Biotech, Inc. About the CHRYSALIS Study. of patients.
FDA Approval 52
52 
Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial
The Pharma Data
MARCH 4, 2021
associate professor of Dermatology at Yale School of Medicine. AA is the second potential treatment indication in dermatology for baricitinib after AD. ” Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as OLUMIANT in the U.S.
Trials 52
52 
Saphnelo (anifrolumab) approved in the US for moderate to severe systemic lupus erythematosus
The Pharma Data
AUGUST 1, 2021
Financial considerations AstraZeneca acquired global rights to Saphnelo through an exclusive license and collaboration agreement with Medarex, Inc. The Phase III trial in SLE using subcutaneous delivery has been initiated and additional Phase III trials are planned for lupus nephritis, cutaneous lupus erythematosus and myositis.
Trials 52
52 
Novartis key growth drivers and launches continue momentum in Q1, maintaining confidence in growth. Group guidance for FY 2021 confirmed. | Novartis
The Pharma Data
APRIL 26, 2021
COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. billion declined, mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene. Adakveo sales reached USD 37 million. Free cash flow¹ of USD 1.6 Tislelizumab.
Sales 40
40 
Clinical Catch-Up: January 18-22 | BioSpace
The Pharma Data
JANUARY 24, 2021
The drug was well tolerated and demonstrated clinically meaningful improvement in the Dermatology Life Quality Index (DLQI) and Patient-Oriented Eczema Measure IPOEM). The drug was licensed from Immutep Limited. The drug is an oral therapy for inflammatory diseases and effects multiple pathways, TH1, Th2 and Th17.
Trials 52
52 
Tezepelumab regulatory submission accepted and granted FDA Priority Review in the US for the treatment of patients with asthma
The Pharma Data
JULY 8, 2021
AstraZeneca’s Biologics License Application (BLA) for tezepelumab has been accepted and granted Priority Review for the treatment of asthma from the US Food and Drug Administration (FDA). Tezepelumab is being developed by AstraZeneca in collaboration with Amgen.
Trials 52
52 
GSK receives FDA accelerated approval for JEMPERLI (dostarlimab-gxly) for adult patients with mismatch repair-deficient (dMMR) recurrent or advanced solid tumours
The Pharma Data
AUGUST 17, 2021
This new indication follows an FDA priority review of the Biologics License Application and is based on the collective results from the dMMR endometrial cancer cohort A1 and the dMMR solid-tumour (non-endometrial cancer) cohort F of the ongoing GARNET trial. [vii] JEMPERLI was discovered by AnaptysBio and licensed to TESARO, Inc.,
FDA Approval 52
52 
Let's personalize your content